JP2017514871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514871A5 JP2017514871A5 JP2016566909A JP2016566909A JP2017514871A5 JP 2017514871 A5 JP2017514871 A5 JP 2017514871A5 JP 2016566909 A JP2016566909 A JP 2016566909A JP 2016566909 A JP2016566909 A JP 2016566909A JP 2017514871 A5 JP2017514871 A5 JP 2017514871A5
- Authority
- JP
- Japan
- Prior art keywords
- glyx
- administering
- patient
- effective amount
- cognitive impairment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989183P | 2014-05-06 | 2014-05-06 | |
| US61/989,183 | 2014-05-06 | ||
| PCT/US2015/029477 WO2015171770A1 (en) | 2014-05-06 | 2015-05-06 | Combinations of nmdar modulating compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020083060A Division JP2020138973A (ja) | 2014-05-06 | 2020-05-11 | Ｎｍｄａｒ調節化合物の組合せ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017514871A JP2017514871A (ja) | 2017-06-08 |
| JP2017514871A5 true JP2017514871A5 (cg-RX-API-DMAC7.html) | 2018-06-14 |
Family
ID=54392956
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566909A Pending JP2017514871A (ja) | 2014-05-06 | 2015-05-06 | Ｎｍｄａｒ調節化合物の組合せ |
| JP2020083060A Pending JP2020138973A (ja) | 2014-05-06 | 2020-05-11 | Ｎｍｄａｒ調節化合物の組合せ |
| JP2022116942A Pending JP2022159322A (ja) | 2014-05-06 | 2022-07-22 | Ｎｍｄａｒ調節化合物の組合せ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020083060A Pending JP2020138973A (ja) | 2014-05-06 | 2020-05-11 | Ｎｍｄａｒ調節化合物の組合せ |
| JP2022116942A Pending JP2022159322A (ja) | 2014-05-06 | 2022-07-22 | Ｎｍｄａｒ調節化合物の組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170072005A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3139943A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2017514871A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20220102662A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106659762A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015256075B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016025910A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2947976A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016014581A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2721948C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015171770A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2017107558A (ru) | 2014-09-15 | 2018-10-18 | Руджен Холдингс (Кайман) Лимитед | Производные пирролопиримидина в качестве антагонистов nmda-рецептора nr2b |
| US20180271869A1 (en) * | 2014-09-22 | 2018-09-27 | Jie Liu | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016126869A1 (en) | 2015-02-04 | 2016-08-11 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists |
| PL3297619T3 (pl) * | 2015-05-22 | 2023-02-13 | Vistagen Therapeutics, Inc. | Terapeutyczne zastosowania L-4-chlorokinureniny |
| MX380424B (es) | 2015-06-01 | 2025-03-12 | Rugen Holdings Cayman Ltd | Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b. |
| BR112018007681A2 (pt) * | 2015-10-16 | 2018-11-06 | Univ Northwestern | combinação farmacêutica de um antipsicótico atípico e um modulador de nmda para o tratamento de esquizofrenia, distúrbio bipolar, comprometimento cognitivo e distúrbio depressivo maior |
| JP2018534362A (ja) * | 2015-10-16 | 2018-11-22 | スキティアン バイオサイエンシーズ インコーポレーテッドＳｃｙｔｈｉａｎ Ｂｉｏｓｃｉｅｎｃｅｓ Ｉｎｃ． | 外傷性脳損傷を処置するための方法および組成物 |
| JP6967532B2 (ja) * | 2016-05-25 | 2021-11-17 | ナショナル ヘルス リサーチ インスティテューツNational Health Research Institutes | 付加的抗うつ剤組成物及びその使用方法 |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| CN107550907A (zh) * | 2017-08-29 | 2018-01-09 | 昆明医科大学 | 治疗精神分裂症的药物及验证药物的动物模型构建方法 |
| WO2019113102A1 (en) * | 2017-12-05 | 2019-06-13 | Naurex Inc. | Nmda receptor modulators (rapastinel) combination for use in combined treatment (sleep and cns disorder) |
| ES2907692T3 (es) | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
| CN110343050B (zh) * | 2018-04-04 | 2021-09-24 | 上海键合医药科技有限公司 | 芳香类化合物及其制备方法和用途 |
| CN109223785A (zh) * | 2018-10-29 | 2019-01-18 | 中国药科大学 | 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用 |
| WO2020146878A1 (en) * | 2019-01-11 | 2020-07-16 | Naurex Inc. | Salt and crystalline forms of rapastinel |
| WO2020163966A1 (en) | 2019-02-14 | 2020-08-20 | Algernon Pharmaceuticals Inc. | Compositions and methods for treating idiopathic pulmonary fibrosis |
| WO2021081624A1 (en) | 2019-10-28 | 2021-05-06 | Algernon Pharmaceuticals Inc. | Use of glutamate 2b receptor antagonists and sigma receptor agonsists as antitussives |
| CN113234036B (zh) * | 2021-05-12 | 2023-07-14 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
| KR20230056971A (ko) * | 2021-10-21 | 2023-04-28 | 삼육대학교산학협력단 | 신규 케타민 유도체를 포함하는 우울증 예방 또는 치료용 약학적 조성물 |
| KR20250065690A (ko) | 2022-09-14 | 2025-05-13 | 더 보드 오브 트러스티스 오브 더 릴랜드 스탠포드 주니어 유니버시티 | 이보가 알칼로이드의 조성물 및 치료 방법 |
| WO2025065271A1 (en) * | 2023-09-26 | 2025-04-03 | Liangzhu Laboratory | Methods and devices for treating depression |
| WO2025124571A1 (zh) * | 2023-12-14 | 2025-06-19 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
| CN119174765A (zh) * | 2024-09-04 | 2024-12-24 | 复旦大学附属中山医院 | Gsdme蛋白的小分子抑制剂在肿瘤及其免疫治疗中的作用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597809A (en) * | 1994-06-23 | 1997-01-28 | Massachusetts Eye & Ear Infirmary | Treatment of optic neuritis |
| KR20060030469A (ko) * | 2003-05-27 | 2006-04-10 | 포레스트 래보러토리즈, 인코포레이티드 | 우울증 및 그 밖의 기분장애의 치료를 위한 ｎｍｄａ수용체 길항제 및 선택적 세로토닌 재흡수 억제제의 배합물 |
| GB0523998D0 (en) * | 2005-11-25 | 2006-01-04 | Merck Sharp & Dohme | Therapeutic agents |
| US20090275597A1 (en) * | 2008-05-02 | 2009-11-05 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
| TWI403319B (zh) * | 2008-07-03 | 2013-08-01 | Panmira Pharmaceuticals Llc | 前列腺素ｄ2受體之雜烷基拮抗劑 |
| EP2381941A4 (en) * | 2008-12-29 | 2012-08-01 | Univ Vanderbilt | 3.1.0 BICYCLIC GLYTI INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| PL2582366T3 (pl) * | 2010-06-15 | 2016-04-29 | Gruenenthal Gmbh | Kombinacja farmaceutyczna do leczenia bólu |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| MX2014010939A (es) * | 2012-03-12 | 2014-11-13 | Janssen Pharmaceutica Nv | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento. |
-
2015
- 2015-05-06 KR KR1020227022906A patent/KR20220102662A/ko not_active Ceased
- 2015-05-06 JP JP2016566909A patent/JP2017514871A/ja active Pending
- 2015-05-06 RU RU2016146714A patent/RU2721948C2/ru active
- 2015-05-06 US US15/309,390 patent/US20170072005A1/en not_active Abandoned
- 2015-05-06 CA CA2947976A patent/CA2947976A1/en not_active Abandoned
- 2015-05-06 BR BR112016025910A patent/BR112016025910A8/pt not_active Application Discontinuation
- 2015-05-06 AU AU2015256075A patent/AU2015256075B2/en not_active Ceased
- 2015-05-06 CN CN201580031430.2A patent/CN106659762A/zh active Pending
- 2015-05-06 KR KR1020167034031A patent/KR20170013890A/ko not_active Ceased
- 2015-05-06 WO PCT/US2015/029477 patent/WO2015171770A1/en not_active Ceased
- 2015-05-06 MX MX2016014581A patent/MX2016014581A/es unknown
- 2015-05-06 EP EP15789211.8A patent/EP3139943A4/en not_active Withdrawn
-
2020
- 2020-05-11 JP JP2020083060A patent/JP2020138973A/ja active Pending
-
2022
- 2022-07-22 JP JP2022116942A patent/JP2022159322A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514871A5 (cg-RX-API-DMAC7.html) | ||
| KR20220012274A9 (ko) | 플루오린 함유 화합물 및 이의 항암 의학적 용도 | |
| EP3558424A4 (en) | DRUG DELIVERY SYSTEMS AND METHODS | |
| EP3399972A4 (en) | LOW-DOSED THERAPEUTIC TREATMENT | |
| IL254207B (en) | Oral care compositions and methods of use | |
| JP2016518337A5 (cg-RX-API-DMAC7.html) | ||
| HUE053309T2 (hu) | Új sók és gyógyászati készítmények gyulladásos betegségek kezelésére | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| JP2015503422A5 (cg-RX-API-DMAC7.html) | ||
| HUE058731T2 (hu) | Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai | |
| IL260955A (en) | A mini tablet for oral administration containing sacubitril and valsartan for the treatment of heart failure | |
| HUE060496T2 (hu) | Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére | |
| EP3253451A4 (en) | Diagnosis and treatment of chronic pain | |
| SI4335517T1 (sl) | Dajanje in odmerek diaminofenotiazinov | |
| HUE071358T2 (hu) | Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk | |
| JP2015522522A5 (cg-RX-API-DMAC7.html) | ||
| IL280475A (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| MA46621A (fr) | Traitements combinés comprenant l'administration d'imidazopyrazinones | |
| MX2017003513A (es) | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia. | |
| HUE058354T2 (hu) | Hidrofil bevonattal rendelkezõ higiénikus orvosi eszközök és eljárások azok kialakítására | |
| HUE062784T2 (hu) | Indolinon vegyületek és alkalmazásuk fibrotikus betegségek kezelésében | |
| IL287704A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| HUE066272T2 (hu) | Terápiás szer az amiotrófiás laterálszklerózisra és a kezelésre szolgáló készítmény | |
| IL264407A (en) | Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases | |
| UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині |